J&J’s new esketamine drug for depression, Spravato, not worth the money or the risk, watchdog says - The Philadelphia Inquirer

Submitted by Anonymous (not verified) on Mon, 05/13/2019 - 07:00

J&J’s new esketamine drug for depression, Spravato, not worth the money or the risk, watchdog says  The Philadelphia InquirerThe nasal spray for treatment-resistant depression was called overpriced. ICER also found an absence of long-term safety data.